This study explores how conjugating a BMP1/TLL inhibitor to a small-molecule non‑covalent human serum albumin (HSA) binder (AlbuBinder 1) dramatically extends its in vivo half‑life in mice.
AlbuBinder–inhibitor conjugate showed >20‑fold increased half‑life (>48 h vs. 3 h), maintaining BMP1/TLL inhibition—demonstrating albumin-binding as an effective pharmacokinetic enhancement strategy.
GenOway-developed HSA knock‑in mouse (HSA KI/KI), expressing human serum albumin in place of endogenous albumin
Pharmacokinetics, Half‑life extension, Albumin-binding therapeutics, Protease inhibition
Knockin, Human serum albumin locus, Homozygous HSA expression, Pharmacokinetic modeling
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
